Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 5673 | 8.99 |
09:34 ET | 11495 | 9.0869 |
09:36 ET | 5198 | 8.83 |
09:38 ET | 195 | 8.7624 |
09:39 ET | 3869 | 8.8 |
09:41 ET | 1700 | 8.79 |
09:43 ET | 1158 | 8.8 |
09:45 ET | 500 | 8.77 |
09:48 ET | 625 | 8.86 |
09:50 ET | 1001 | 8.78 |
09:56 ET | 2263 | 8.77 |
09:57 ET | 2485 | 8.82 |
09:59 ET | 691 | 8.9552 |
10:01 ET | 2300 | 8.925 |
10:03 ET | 705 | 8.89 |
10:06 ET | 548 | 8.97 |
10:08 ET | 235 | 8.95 |
10:10 ET | 3648 | 8.97 |
10:12 ET | 1448 | 9.08 |
10:14 ET | 6278 | 9.07 |
10:15 ET | 1413 | 9.12 |
10:17 ET | 1144 | 9.13 |
10:19 ET | 578 | 9.13 |
10:21 ET | 2811 | 9.2 |
10:24 ET | 11708 | 9.29 |
10:26 ET | 16578 | 9.28 |
10:28 ET | 1699 | 9.24 |
10:30 ET | 1673 | 9.275 |
10:32 ET | 16249 | 9.34 |
10:33 ET | 642 | 9.35 |
10:35 ET | 784 | 9.3206 |
10:37 ET | 1077 | 9.395 |
10:39 ET | 3499 | 9.4 |
10:42 ET | 900 | 9.44 |
10:44 ET | 1182 | 9.41 |
10:46 ET | 627 | 9.39 |
10:48 ET | 2370 | 9.43 |
10:50 ET | 778 | 9.365 |
10:51 ET | 1750 | 9.33 |
10:53 ET | 100 | 9.335 |
10:55 ET | 2050 | 9.28 |
10:57 ET | 5266 | 9.335 |
11:00 ET | 6606 | 9.21 |
11:02 ET | 2034 | 9.1501 |
11:04 ET | 2100 | 9.1796 |
11:06 ET | 300 | 9.185 |
11:08 ET | 1297 | 9.16 |
11:09 ET | 288 | 9.16 |
11:11 ET | 1700 | 9.08 |
11:13 ET | 100 | 9.09 |
11:15 ET | 100 | 9.145 |
11:18 ET | 1834 | 9.16 |
11:20 ET | 100 | 9.16 |
11:22 ET | 800 | 9.16 |
11:24 ET | 1733 | 9.18 |
11:26 ET | 388 | 9.17 |
11:27 ET | 200 | 9.18 |
11:29 ET | 485 | 9.24 |
11:31 ET | 3656 | 9.1534 |
11:33 ET | 1797 | 9.05 |
11:36 ET | 444 | 9.0567 |
11:38 ET | 5261 | 9.005 |
11:40 ET | 4028 | 8.91 |
11:42 ET | 1100 | 8.9666 |
11:44 ET | 1721 | 8.9 |
11:45 ET | 2508 | 8.95 |
11:47 ET | 1580 | 9.01 |
11:51 ET | 1605 | 8.975 |
11:54 ET | 13231 | 9.06 |
11:56 ET | 900 | 9.05 |
11:58 ET | 300 | 9.0795 |
12:00 ET | 575 | 9.07 |
12:03 ET | 200 | 9.1 |
12:05 ET | 305 | 9.18 |
12:07 ET | 2257 | 9.155 |
12:09 ET | 500 | 9.22 |
12:12 ET | 691 | 9.2767 |
12:14 ET | 667 | 9.19 |
12:16 ET | 200 | 9.1991 |
12:18 ET | 200 | 9.23 |
12:20 ET | 588 | 9.18 |
12:21 ET | 400 | 9.21 |
12:23 ET | 1686 | 9.1433 |
12:25 ET | 835 | 9.14 |
12:27 ET | 500 | 9.08 |
12:30 ET | 202 | 9.08 |
12:32 ET | 1748 | 9.045 |
12:34 ET | 500 | 9.07 |
12:38 ET | 105 | 9.04 |
12:39 ET | 300 | 9.06 |
12:41 ET | 5413 | 9.04 |
12:43 ET | 15985 | 8.94 |
12:45 ET | 745 | 9.01 |
12:48 ET | 900 | 8.96 |
12:50 ET | 300 | 9 |
12:52 ET | 1621 | 8.97 |
12:54 ET | 1489 | 8.9834 |
12:56 ET | 200 | 8.955 |
12:57 ET | 100 | 8.955 |
12:59 ET | 1657 | 9.03 |
01:01 ET | 928 | 9.01 |
01:03 ET | 400 | 9.01 |
01:06 ET | 307 | 9 |
01:10 ET | 205 | 9 |
01:12 ET | 1058 | 8.98 |
01:14 ET | 212 | 8.98 |
01:15 ET | 500 | 8.99 |
01:17 ET | 551 | 8.99 |
01:19 ET | 108 | 8.995 |
01:21 ET | 836 | 9.07 |
01:24 ET | 100 | 9.04 |
01:26 ET | 750 | 9.005 |
01:30 ET | 881 | 8.98 |
01:32 ET | 146 | 9.02 |
01:33 ET | 1328 | 8.995 |
01:35 ET | 833 | 9 |
01:37 ET | 772 | 8.926 |
01:39 ET | 627 | 9 |
01:44 ET | 299 | 8.975 |
01:48 ET | 235 | 8.975 |
01:50 ET | 322 | 8.99 |
01:51 ET | 300 | 9 |
01:53 ET | 1191 | 9.01 |
02:00 ET | 140 | 9.014 |
02:02 ET | 1171 | 9.02 |
02:04 ET | 20190 | 8.89 |
02:06 ET | 800 | 8.95 |
02:09 ET | 6593 | 8.965 |
02:11 ET | 881 | 8.94 |
02:13 ET | 199 | 8.97 |
02:15 ET | 308 | 8.94 |
02:18 ET | 500 | 8.89 |
02:20 ET | 1927 | 8.88 |
02:22 ET | 100 | 8.88 |
02:26 ET | 154 | 8.935 |
02:27 ET | 1665 | 8.9234 |
02:29 ET | 1200 | 8.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 314.7M | -2.3x | --- |
Lexeo Therapeutics Inc | 316.7M | -3.7x | --- |
Design Therapeutics Inc | 319.3M | -6.5x | --- |
enGene Holdings Inc | 321.4M | -1.5x | --- |
PepGen Inc | 301.8M | -2.9x | --- |
Zentalis Pharmaceuticals Inc | 295.8M | -1.6x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $314.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.51 |
EPS | $-3.90 |
Book Value | $4.72 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.